-+ 0.00%
-+ 0.00%
-+ 0.00%

ASH 2025 ORAL PRESENTATION: INNOVENT BIOLOGICS ANNOUNCES INITIAL RESULTS OF THE FIRST-IN-HUMAN PHASE 1 STUDY OF TRISPECIFIC ANTIBODY IBI3003 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Reuters·12/08/2025 01:03:03

Please log in to view news